Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.76 |
| ▸ | MTOR | P42345 | 16/20 | 0.76 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.76 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.76 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.76 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.76 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.76 |
| ▸ | STK10 | O94804 | 1/20 | 0.76 |
| ▸ | PAK4 | O96013 | 1/20 | 0.76 |
| ▸ | ABL1 | P00519 | 1/20 | 0.76 |
| ▸ | EGFR | P00533 | 1/20 | 0.76 |
| ▸ | FGR | P09769 | 1/20 | 0.76 |
| ▸ | FER | P16591 | 1/20 | 0.76 |
| ▸ | PRKCA | P17252 | 1/20 | 0.76 |
| ▸ | JAK1 | P23458 | 1/20 | 0.76 |
| ▸ | TEC | P42680 | 1/20 | 0.76 |
| ▸ | SYK | P43405 | 1/20 | 0.76 |
| ▸ | PRKDC | P78527 | 1/20 | 0.76 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.76 |
| ▸ | BTK | Q06187 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3458050 | 1.00 | PIK3CA (0.76) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4440454 | 1.00 | PIK3CA (0.76) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4448342 | 0.92 | PIK3CA (0.76) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4441726 | 0.91 | PIK3CA (0.64) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL15668201 | 0.91 | PIK3CA (0.79) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL16267999 | 0.91 | PIK3CA (0.79) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4442373 | 0.91 | PIK3CA (0.63) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4445879 | 0.91 | PIK3CA (0.63) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4439825 | 0.91 | PIK3CA (0.65) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4435723 | 0.90 | PIK3CA (0.79) | PIK3CAMTORPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114949-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2009-11-11 | — | — | EP | claimed |
| WO-2008070740-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | claimed |
| WO-2026106912-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026090116-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090245-A1 | USE OF RAS INHIBITORS FOR TREATING CANCER | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20250319187-A1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4620531-A2 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250255964-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-08-14 | — | — | US | disclosed |
| US-20250049810-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. | 2025-02-13 | — | — | US | disclosed |
| WO-2024081363-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2024-04-18 | — | — | WO | disclosed |
| EP-4346898-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-2475659-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| EP-2405916-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | Genentech, Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| WO-2011161216-A1 | HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011029802-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| EP-2254571-A2 | COMBINATIONS OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | Genentech, Inc. (US) | 2010-12-01 | — | — | EP | disclosed |
| WO-2010105008-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | GENENTECH, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| EP-2205242-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | Genentech, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009117277-A2 | COMBINATIONS OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009036082-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319187-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | PIK3CA 79/4885MTOR 196/4885PIK3CD 146/4885 |
| US-20250049810-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | KRAS, HRAS, NRAS | PIK3CA 774/4885MTOR 405/4885PIK3CD 1080/4885 |
| US-20250255964-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | PIK3CA 79/4885MTOR 196/4885PIK3CD 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.